<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pharming Group Nv — News on 6ix</title>
<link>https://6ix.com/company/pharming-group-nv</link>
<description>Latest news and press releases for Pharming Group Nv on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pharming-group-nv" rel="self" type="application/rss+xml" />
<item>
<title>Pharming Group to report first quarter 2026 financial results and provide business update on May 7</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-7</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-7</guid>
<pubDate>Thu, 23 Apr 2026 06:00:00 GMT</pubDate>
<description>Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the first quarter 2026 and provide a business update on Thursday, May 7, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CEST/07:30 am EDT. To participate in the conference call or to watch the live webcast, please register in a</description>
</item>
<item>
<title>Pharming Group announces the 2026 Annual General Meeting of Shareholders</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-announces-the-2026-annual-general-meeting-of-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-announces-the-2026-annual-general-meeting-of-shareholders</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the</description>
</item>
<item>
<title>Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-receives-positive-chmp-opinion-for-joenjar-leniolisib-for-the-treatment-of-apds-in-adult-and-pediatric-patients-12-years-and-older</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-receives-positive-chmp-opinion-for-joenjar-leniolisib-for-the-treatment-of-apds-in-adult-and-pediatric-patients-12-years-and-older</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ)</description>
</item>
<item>
<title>Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-announces-approval-of-joenjar-leniolisib-in-japan-for-the-treatment-of-apds-in-patients-aged-4-years-and-older</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-announces-approval-of-joenjar-leniolisib-in-japan-for-the-treatment-of-apds-in-patients-aged-4-years-and-older</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval is based on positive Phase III data from</description>
</item>
<item>
<title>Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-reports-fourth-quarter-and-full-year-2025-financial-results-delivering-strong-revenue-growth-and-profitability-with-positive-cash-flow</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-reports-fourth-quarter-and-full-year-2025-financial-results-delivering-strong-revenue-growth-and-profitability-with-positive-cash-flow</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth</description>
</item>
<item>
<title>Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-12</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-12</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will</description>
</item>
<item>
<title>Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Tue, 17 Feb 2026 07:00:00 GMT</pubDate>
<description>Leiden, the Netherlands, February 17, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held virtually on February 25-26, 2026. Fabrice Chouraqui, Chief Executive Officer, and Anurag Relan, M.D., Chief Medical Officer, will present on Wednesday, February 25 at 12:40pm ET/18:40 CET. A live webcast and replay of the presentation will be made avai</description>
</item>
<item>
<title>Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-announces-2026-financial-guidance-and-highlights-rare-disease-0</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-announces-2026-financial-guidance-and-highlights-rare-disease-0</guid>
<pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
<description>Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and</description>
</item>
<item>
<title>Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-receives-complete-response-201700362</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-receives-complete-response-201700362</guid>
<pubDate>Sun, 01 Feb 2026 20:17:00 GMT</pubDate>
<description>Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. The FDA raise</description>
</item>
<item>
<title>Pharming Group reports preliminary 2025 revenues and announces Investor Day</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-reports-preliminary-2025-revenues-and-announces-investor-day-2026-01-0</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-reports-preliminary-2025-revenues-and-announces-investor-day-2026-01-0</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its</description>
</item>
<item>
<title>Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-participate-oppenheimer-movers-rare-disease-summit-2025-12-08</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-participate-oppenheimer-movers-rare-disease-summit-2025-12-08</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the</description>
</item>
<item>
<title>Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-reports-third-quarter-2025-financial-results-significant-growth-0</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-reports-third-quarter-2025-financial-results-significant-growth-0</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to</description>
</item>
<item>
<title>Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-participate-fireside-chat-jefferies-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-participate-fireside-chat-jefferies-global-healthcare-conference</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will</description>
</item>
<item>
<title>Pharming Group to report third quarter 2025 financial results and provide business update on November 6</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-report-third-quarter-2025-financial-results-and-provide-business</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-report-third-quarter-2025-financial-results-and-provide-business</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its</description>
</item>
<item>
<title>Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-announces-presentations-2025-acaai-annual-scientific-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-announces-presentations-2025-acaai-annual-scientific-meeting</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts</description>
</item>
<item>
<title>Pharming Group provides update on previously announced G&A expense reduction plan</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-provides-update-previously-announced-ga-expense-reduction-plan-2025-0</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-provides-update-previously-announced-ga-expense-reduction-plan-2025-0</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation</description>
</item>
<item>
<title>Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-announces-us-fda-acceptance-and-priority-review-supplemental-new-0</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-announces-us-fda-acceptance-and-priority-review-supplemental-new-0</guid>
<pubDate>Wed, 01 Oct 2025 04:00:00 GMT</pubDate>
<description>If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare</description>
</item>
<item>
<title>Pharming Group promoted to the Euronext AMX® index</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-promoted-euronext-amxr-index-2025-09-10-0</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-promoted-euronext-amxr-index-2025-09-10-0</guid>
<pubDate>Wed, 10 Sep 2025 04:00:00 GMT</pubDate>
<description>Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has</description>
</item>
<item>
<title>Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-present-hc-wainwright-27th-annual-global-investment-conference-2025-09</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-present-hc-wainwright-27th-annual-global-investment-conference-2025-09</guid>
<pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
<description>Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will</description>
</item>
<item>
<title>Pharming Group appoints Kenneth Lynard as Chief Financial Officer</title>
<link>https://6ix.com/company/pharming-group-nv/news/pharming-group-appoints-kenneth-lynard-chief-financial-officer-2025-09-02-0</link>
<guid isPermaLink="true">https://6ix.com/company/pharming-group-nv/news/pharming-group-appoints-kenneth-lynard-chief-financial-officer-2025-09-02-0</guid>
<pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
<description>Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment</description>
</item>
</channel>
</rss>